Reviewing Marinus Pharmaceuticals Inc. (MRNS)’s and FibroGen Inc. (NASDAQ:FGEN)’s results

Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) and FibroGen Inc. (NASDAQ:FGEN) compete with each other in the Biotechnology sector. We will analyze and contrast their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Marinus Pharmaceuticals Inc. N/A 0.00 31.35M -0.86 0.00
FibroGen Inc. 212.96M 22.81 86.42M -0.88 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Marinus Pharmaceuticals Inc. and FibroGen Inc.

Profitability

Table 2 provides Marinus Pharmaceuticals Inc. and FibroGen Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Marinus Pharmaceuticals Inc. 0.00% -65.6% -60.7%
FibroGen Inc. -40.58% -22.3% -12.8%

Risk and Volatility

A 3.24 beta indicates that Marinus Pharmaceuticals Inc. is 224.00% more volatile compared to S&P 500. FibroGen Inc.’s 1.74 beta is the reason why it is 74.00% more volatile than S&P 500.

Liquidity

The Current Ratio and Quick Ratio of Marinus Pharmaceuticals Inc. are 5.9 and 5.9 respectively. Its competitor FibroGen Inc.’s Current Ratio is 6.8 and its Quick Ratio is 6.8. FibroGen Inc. can pay off short and long-term obligations better than Marinus Pharmaceuticals Inc.

Analyst Recommendations

The table given features the ratings and recommendations for Marinus Pharmaceuticals Inc. and FibroGen Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Marinus Pharmaceuticals Inc. 0 1 4 2.80
FibroGen Inc. 0 0 5 3.00

Marinus Pharmaceuticals Inc.’s consensus price target is $15.42, while its potential upside is 307.94%. Competitively FibroGen Inc. has a consensus price target of $75, with potential upside of 32.11%. The data provided earlier shows that Marinus Pharmaceuticals Inc. appears more favorable than FibroGen Inc., based on analyst opinion.

Insider & Institutional Ownership

Marinus Pharmaceuticals Inc. and FibroGen Inc. has shares held by institutional investors as follows: 72.2% and 67.3%. Marinus Pharmaceuticals Inc.’s share held by insiders are 0.5%. On the other hand, insiders held about 4.3% of FibroGen Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Marinus Pharmaceuticals Inc. -14.01% 7.23% -15.24% -45.73% -28.66% 24.04%
FibroGen Inc. 0.27% 3.42% 36.27% -3.63% 6.81% 26.82%

For the past year Marinus Pharmaceuticals Inc. was less bullish than FibroGen Inc.

Summary

FibroGen Inc. beats Marinus Pharmaceuticals Inc. on 7 of the 11 factors.

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. The company is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of genetic orphan disorders, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. The company is also developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreement with Purdue Neuroscience Company. The company was founded in 2003 and is based in Radnor, Pennsylvania.

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.